aap Implantate AG Logo

aap Implantate AG

AAQ1.DE

(1.2)
Stock Price

2,04 EUR

-29.37% ROA

-43.3% ROE

-3.04x PER

Market Cap.

20.641.648,00 EUR

48.79% DER

0% Yield

-44.65% NPM

aap Implantate AG Stock Analysis

aap Implantate AG Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

aap Implantate AG Fundamental Stock Analysis
# Analysis Rating
1 PBV

With a remarkably low PBV ratio (0.38x), the stock offers substantial upside potential at a bargain price.

2 DER

The stock has a minimal amount of debt (26%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

3 Graham Number

Based on the Graham number, this company's stock price appears to be lower than its intrinsic value, signaling a potentially favorable investment choice.

4 ROE

The stock's ROE indicates a negative return (-20.03%) on shareholders' equity, suggesting poor financial performance.

5 ROA

The stock's ROA (-14.15%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

6 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

7 Net Profit Growth

This company's net profit has remained stagnant over the past five years, indicating a lack of growth and making it a less favorable investment option.

8 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

9 Dividend Growth

The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.

10 Dividend

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

11 Buffet Intrinsic Value

The company's stock presents a potential concern as it appears overvalued (-6) by Warren Buffett's formula, indicating that its market price exceeds its estimated intrinsic value.

aap Implantate AG Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

aap Implantate AG Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

aap Implantate AG Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

aap Implantate AG Revenue
Year Revenue Growth
2002 13.256.000
2003 10.891.760 -21.71%
2004 11.358.250 4.11%
2005 14.250.000 20.29%
2006 0 0%
2007 28.006.000 100%
2008 31.884.000 12.16%
2009 33.101.000 3.68%
2010 28.440.000 -16.39%
2011 29.205.000 2.62%
2012 36.414.000 19.8%
2013 27.672.000 -31.59%
2014 30.414.000 9.02%
2015 12.280.000 -147.67%
2016 10.486.000 -17.11%
2017 10.902.000 3.82%
2018 10.781.000 -1.12%
2019 11.739.000 8.16%
2020 9.326.000 -25.87%
2021 12.166.000 23.34%
2022 11.516.000 -5.64%
2023 11.628.000 0.96%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

aap Implantate AG Research and Development Expenses
Year Research and Development Expenses Growth
2002 0
2003 0 0%
2004 0 0%
2005 0 0%
2006 -552.000 100%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 1.147.000 100%
2013 773.000 -48.38%
2014 907.000 14.77%
2015 1.300.000 30.23%
2016 836.000 -55.5%
2017 533.000 -56.85%
2018 502.000 -6.18%
2019 440.000 -14.09%
2020 290.000 -51.72%
2021 246.000 -17.89%
2022 223.000 -10.31%
2023 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

aap Implantate AG General and Administrative Expenses
Year General and Administrative Expenses Growth
2002 4.187.000
2003 3.263.614 -28.29%
2004 0 0%
2005 4.620.000 100%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 2.684.000 100%
2013 2.172.000 -23.57%
2014 2.691.000 19.29%
2015 2.302.000 -16.9%
2016 2.480.000 7.18%
2017 3.094.000 19.84%
2018 3.324.000 6.92%
2019 3.315.000 -0.27%
2020 2.893.000 -14.59%
2021 2.688.000 -7.63%
2022 2.252.000 -19.36%
2023 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

aap Implantate AG EBITDA
Year EBITDA Growth
2002 -292.000
2003 8.160.439 103.58%
2004 1.234.203 -561.19%
2005 2.591.000 52.37%
2006 -928.000 379.2%
2007 4.658.000 119.92%
2008 3.720.000 -25.22%
2009 6.579.000 43.46%
2010 3.482.000 -88.94%
2011 4.184.000 16.78%
2012 5.161.000 18.93%
2013 11.768.000 56.14%
2014 1.336.000 -780.84%
2015 -5.619.000 123.78%
2016 -7.099.000 20.85%
2017 -7.478.000 5.07%
2018 -5.892.000 -26.92%
2019 6.038.000 197.58%
2020 -5.103.000 218.32%
2021 -594.000 -759.09%
2022 -1.567.000 62.09%
2023 -2.212.000 29.16%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

aap Implantate AG Gross Profit
Year Gross Profit Growth
2002 8.589.600
2003 2.917.031 -194.46%
2004 3.963.709 26.41%
2005 9.530.000 58.41%
2006 -4.022.000 336.95%
2007 19.696.000 120.42%
2008 27.243.000 27.7%
2009 27.377.000 0.49%
2010 28.440.000 3.74%
2011 24.925.000 -14.1%
2012 28.561.000 12.73%
2013 21.325.000 -33.93%
2014 21.012.000 -1.49%
2015 10.340.000 -103.21%
2016 8.792.000 -17.61%
2017 9.796.000 10.25%
2018 10.299.000 4.88%
2019 10.606.000 2.89%
2020 7.956.000 -33.31%
2021 10.904.000 27.04%
2022 10.576.000 -3.1%
2023 10.348.000 -2.2%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

aap Implantate AG Net Profit
Year Net Profit Growth
2002 -4.520.000
2003 -15.421.902 70.69%
2004 -139.664 -10942.15%
2005 655.000 121.32%
2006 0 0%
2007 1.511.000 100%
2008 -5.234.000 128.87%
2009 1.938.000 370.07%
2010 51.000 -3700%
2011 395.000 87.09%
2012 2.410.000 83.61%
2013 -2.454.000 198.21%
2014 -456.000 -438.16%
2015 -5.292.000 91.38%
2016 14.629.000 136.17%
2017 -9.271.000 257.79%
2018 -7.666.000 -20.94%
2019 -19.439.000 60.56%
2020 -8.937.000 -117.51%
2021 -2.522.000 -254.36%
2022 -2.564.000 1.64%
2023 -4.128.000 37.89%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

aap Implantate AG Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2002 -8
2003 -27 73.08%
2004 0 0%
2005 0 0%
2006 0 0%
2007 1 0%
2008 -2 100%
2009 1 0%
2010 0 0%
2011 0 0%
2012 1 0%
2013 -1 0%
2014 0 0%
2015 -2 100%
2016 -3 50%
2017 -3 0%
2018 -2 0%
2019 -6 60%
2020 -3 -150%
2021 -1 0%
2022 0 0%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

aap Implantate AG Free Cashflow
Year Free Cashflow Growth
2002 1.554.000
2003 1.735.000 10.43%
2004 -2.133.000 181.34%
2005 718.000 397.08%
2006 1.729.000 58.47%
2007 -6.385.000 127.08%
2008 -3.649.000 -74.98%
2009 707.000 616.12%
2010 -1.792.000 139.45%
2011 -773.000 -131.82%
2012 3.186.000 124.26%
2013 -2.172.000 246.69%
2014 -8.078.000 73.11%
2015 -5.407.000 -49.4%
2016 -7.184.000 24.74%
2017 -6.785.000 -5.88%
2018 -8.082.000 16.05%
2019 -7.456.000 -8.4%
2019 -1.904.000 -291.6%
2020 -4.089.000 53.44%
2021 -2.993.000 -36.62%
2022 -2.378.000 -25.86%
2023 -818 -290964.87%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

aap Implantate AG Operating Cashflow
Year Operating Cashflow Growth
2002 1.554.000
2003 1.735.000 10.43%
2004 -2.133.000 181.34%
2005 718.000 397.08%
2006 1.729.000 58.47%
2007 -299.000 678.26%
2008 544.000 154.96%
2009 4.761.000 88.57%
2010 2.654.000 -79.39%
2011 3.213.000 17.4%
2012 7.088.000 54.67%
2013 3.547.000 -99.83%
2014 -2.945.000 220.44%
2015 -2.265.000 -30.02%
2016 -7.203.000 68.55%
2017 -5.428.000 -32.7%
2018 -5.919.000 8.3%
2019 -5.767.000 -2.64%
2019 -1.357.000 -324.98%
2020 -3.675.000 63.07%
2021 -2.470.000 -48.79%
2022 -1.893.000 -30.48%
2023 -771 -245425.29%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

aap Implantate AG Capital Expenditure
Year Capital Expenditure Growth
2002 0
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 6.086.000 100%
2008 4.193.000 -45.15%
2009 4.054.000 -3.43%
2010 4.446.000 8.82%
2011 3.986.000 -11.54%
2012 3.902.000 -2.15%
2013 5.719.000 31.77%
2014 5.133.000 -11.42%
2015 3.142.000 -63.37%
2016 -19.000 16636.84%
2017 1.357.000 101.4%
2018 2.163.000 37.26%
2019 1.689.000 -28.06%
2019 547.000 -208.78%
2020 414.000 -32.13%
2021 523.000 20.84%
2022 485.000 -7.84%
2023 47 -1054247.83%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

aap Implantate AG Equity
Year Equity Growth
2002 2.171.300.000
2003 627.351.371 -246.11%
2004 15.532.857 -3938.87%
2005 19.366.000 19.79%
2006 21.129.000 8.34%
2007 43.447.000 51.37%
2008 41.303.000 -5.19%
2009 44.715.000 7.63%
2010 44.852.000 0.31%
2011 48.350.000 7.23%
2012 50.866.000 4.95%
2013 48.451.000 -4.98%
2014 45.424.000 -6.66%
2015 40.307.000 -12.7%
2016 54.775.000 26.41%
2017 42.559.000 -28.7%
2018 34.919.000 -21.88%
2019 18.869.000 -85.06%
2020 10.292.000 -83.34%
2021 12.776.000 19.44%
2022 12.827.000 0.4%
2023 10.847.000 -18.25%
2023 14.206.000 23.64%
2024 12.348.000 -15.05%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

aap Implantate AG Assets
Year Assets Growth
2002 4.159.800.000
2003 2.670.275.202 -55.78%
2004 20.447.525 -12959.16%
2005 25.081.000 18.47%
2006 27.554.000 8.98%
2007 68.018.000 59.49%
2008 67.030.000 -1.47%
2009 62.655.000 -6.98%
2010 63.632.000 1.54%
2011 66.151.000 3.81%
2012 68.590.000 3.56%
2013 65.237.000 -5.14%
2014 57.857.000 -12.76%
2015 54.946.000 -5.3%
2016 63.850.000 13.95%
2017 50.469.000 -26.51%
2018 42.221.000 -19.54%
2019 26.288.000 -60.61%
2020 19.706.000 -33.4%
2021 22.954.000 14.15%
2022 20.228.000 -13.48%
2023 19.472.000 -3.88%
2023 21.127.000 7.83%
2024 19.307.000 -9.43%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

aap Implantate AG Liabilities
Year Liabilities Growth
2002 1.988.500.000
2003 2.042.923.831 2.66%
2004 4.914.668 -41467.89%
2005 5.715.000 14%
2006 6.425.000 11.05%
2007 24.571.000 73.85%
2008 25.727.000 4.49%
2009 17.940.000 -43.41%
2010 18.780.000 4.47%
2011 17.801.000 -5.5%
2012 17.724.000 -0.43%
2013 16.786.000 -5.59%
2014 12.433.000 -35.01%
2015 14.639.000 15.07%
2016 9.075.000 -61.31%
2017 7.910.000 -14.73%
2018 7.302.000 -8.33%
2019 7.419.000 1.58%
2020 9.414.000 21.19%
2021 10.178.000 7.51%
2022 7.401.000 -37.52%
2023 8.625.000 14.19%
2023 6.921.000 -24.62%
2024 6.959.000 0.55%

aap Implantate AG Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
1.38
Net Income per Share
-0.62
Price to Earning Ratio
-3.04x
Price To Sales Ratio
1.8x
POCF Ratio
-5.21
PFCF Ratio
-6.07
Price to Book Ratio
1.44
EV to Sales
2.15
EV Over EBITDA
-7.38
EV to Operating CashFlow
-8.24
EV to FreeCashFlow
-7.26
Earnings Yield
-0.33
FreeCashFlow Yield
-0.16
Market Cap
0,02 Bil.
Enterprise Value
0,02 Bil.
Graham Number
4.26
Graham NetNet
-0.36

Income Statement Metrics

Net Income per Share
-0.62
Income Quality
0.58
ROE
-0.43
Return On Assets
-0.26
Return On Capital Employed
-0.34
Net Income per EBT
0.98
EBT Per Ebit
1.05
Ebit per Revenue
-0.43
Effective Tax Rate
0.02

Margins

Sales, General, & Administrative to Revenue
0.23
Research & Developement to Revenue
0.02
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.85
Operating Profit Margin
-0.43
Pretax Profit Margin
-0.45
Net Profit Margin
-0.45

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.36
Free CashFlow per Share
-0.41
Capex to Operating CashFlow
-0.14
Capex to Revenue
0.04
Capex to Depreciation
0.25
Return on Invested Capital
-0.3
Return on Tangible Assets
-0.29
Days Sales Outstanding
72.41
Days Payables Outstanding
454.31
Days of Inventory on Hand
947.2
Receivables Turnover
5.04
Payables Turnover
0.8
Inventory Turnover
0.39
Capex per Share
0.05

Balance Sheet

Cash per Share
0,20
Book Value per Share
1,31
Tangible Book Value per Share
1.06
Shareholders Equity per Share
1.31
Interest Debt per Share
0.66
Debt to Equity
0.49
Debt to Assets
0.27
Net Debt to EBITDA
-1.2
Current Ratio
1.81
Tangible Asset Value
0,01 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
12169000
Working Capital
0,00 Bil.
Intangibles to Total Assets
0.1
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
6168500
Debt to Market Cap
0.26

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

aap Implantate AG Dividends
Year Dividends Growth

aap Implantate AG Profile

About aap Implantate AG

aap Implantate AG, a medical device company, develops, manufactures, and markets trauma products for orthopedics in Germany, the United States, and internationally. It offers LOQTEQ, an anatomical plating system for fracture treatment; and a range of cannulated screws, standard plates, and screws. The company sells its products directly to hospitals, buying syndicates, and hospital groups, as well as through a network of distributors under the aap brand name. aap Implantate AG was founded in 1990 and is headquartered in Berlin, Germany.

CEO
Mr. Rubino Di Girolamo
Employee
87
Address
Lorenzweg 5
Berlin, 12099

aap Implantate AG Executives & BODs

aap Implantate AG Executives & BODs
# Name Age
1 Mr. Rubino Di Girolamo
Chairman of the Management Board & Chief Executive Officer
70
2 Ms. Agnieszka Mierzejewska
Member of Management Board & Chief Operating Officer
70
3 Fabian Franke
Head of Investor Relations
70

aap Implantate AG Competitors

SÜSS MicroTec SE Logo
SÜSS MicroTec SE

SMHN.DE

(2.5)
Medigene AG Logo
Medigene AG

MDG1.DE

(1.0)
Stratec SE Logo
Stratec SE

SBS.DE

(3.0)
Biofrontera AG Logo
Biofrontera AG

B8F.DE

(1.2)
Heidelberg Pharma AG Logo
Heidelberg Pharma AG

HPHA.DE

(1.5)